Minerva Neurosciences CEO to Present at Citizens Life Sciences Conference
Event summary
- Remy Luthringer, PhD, CEO of Minerva Neurosciences, will present at The Citizens Life Sciences Conference on March 10, 2026, at 9:35 AM ET.
- The event will feature a company presentation and is being held in Miami, FL.
- Minerva is currently initiating a confirmatory Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia.
The big picture
Minerva Neurosciences' participation in The Citizens Life Sciences Conference underscores its focus on advancing its lead candidate, roluperidone, through critical clinical stages. The biopharmaceutical sector is highly competitive, with significant emphasis on innovative CNS therapies. Minerva's ability to secure investor interest and partnerships during this event could be pivotal for its long-term success.
What we're watching
- Clinical Trial Progress
- The pace at which Minerva advances its Phase 3 trial for roluperidone will be critical for its strategic positioning in the CNS disorder market.
- Investor Sentiment
- How the conference presentation impacts investor confidence and potential funding or partnerships for Minerva.
- Competitive Dynamics
- Whether Minerva can differentiate itself in the crowded CNS disorder treatment space.
Related topics